Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap
Some four years after it reported its first batch of pivotal trial data, Tetraphase finally secured FDA approval for its lead antibiotic, eravacycline, for complicated intra-abdominal infections in 2018. But like many of its peers, merely securing approval was only the first hurdle.
The bigger obstacle was reaping the returns in a “broken” market for antibiotics. On Monday, the Massachusetts-based company said it was being acquired by AcelRx in an all-stock deal valued at a paltry $14.4 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
